CT 海外癌症临床试验导航 公开信息导航，不做医疗判断

海外临床试验导航

卵巢癌

帮助用户按高级别浆液性、BRCA、HRD、铂敏感/铂耐药、PARP 等方向检索海外公开临床试验。

中文医学标准名
卵巢恶性肿瘤
英文医学标准名
Ovarian Cancer
试验数据最后同步
2026-07-10

Synced trials

当前同步到的治疗类试验

以下记录来自公开临床试验数据库，已按招募状态、治疗目的、干预类型和癌症相关性做初步过滤。本站不判断患者是否符合入组条件，请以官方页面、医生和研究团队意见为准。

最后同步日期：2026-07-10 · 当前显示 140 条

招募状态和入组条件可能随时变化。请以官方页面、医院和研究机构信息为准，并带给主治医生或肿瘤科医生讨论。

状态
全部
试验阶段
全部
治疗类型
全部
国家/地区
全部
正在招募 Phase 1 药物
clinicaltrials.gov NCT07690189

Phase 1 Study of NTB-928 in R/R OC

适用疾病
Relapsed/Refractory Ovarian Carcinoma
干预
NTB-928
地点
United States
申办方
TeneoSeven, Inc.
正在招募 Phase 3 生物制剂药物手术/操作
clinicaltrials.gov NCT06580314

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

适用疾病
Fallopian Tube Endometrioid Adenocarcinoma；Fallopian Tube High Grade Serous Adenocarcinoma；FIGO Stage III Ovarian Cancer 2014
干预
Bevacizumab，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点
United States，Japan，Puerto Rico
申办方
NRG Oncology
即将招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT07504588

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

适用疾病
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma；Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma；Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma
干预
Anti-VEGF Monoclonal Antibody，Bevacizumab，Biospecimen Collection，Carboplatin
地点
未列出
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 药物
clinicaltrials.gov NCT06971744

Autophagy Maintenance (AUTOMAIN)

适用疾病
Ovarian Cancer
干预
Hydroxychloroquine，Nelfinavir，Bevacizumab
地点
United States
申办方
Medical University of South Carolina
正在招募 Phase 1 药物
clinicaltrials.gov NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

适用疾病
Carcinoma, Non-Small Cell Lung；Squamous Cell Carcinoma of Head and Neck；HER2 Negative Breast Neoplasms
干预
sigvotatug vedotin，pembrolizumab，cisplatin，carboplatin
地点
United States，France，South Korea，Spain 等 3 个
申办方
Seagen, a wholly owned subsidiary of Pfizer
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT04585958

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

适用疾病
Metastatic Malignant Solid Neoplasm；Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma；Unresectable Malignant Solid Neoplasm
干预
Biopsy Procedure，Biospecimen Collection，Computed Tomography，Echocardiography Test
地点
United States
申办方
National Cancer Institute (NCI)
正在招募 Phase 1, Phase 2 生物制剂药物其他
clinicaltrials.gov NCT07480954

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

适用疾病
Epithelial Ovarian Cancer；Primary Peritoneal Carcinoma；Fallopian Tube Carcinoma
干预
Dual-target CAR-NK cell product，Lymphodepleting chemotherapy，Standard supportive care
地点
China
申办方
Beijing Biotech
正在招募 Phase 1 药物
clinicaltrials.gov NCT05005403

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

适用疾病
Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Micro Satellite Stable Colorectal Cancer
干预
Azirkitug，Budigalimab，Bevacizumab，Telisotuzumab Adizutecan
地点
United States，Canada，Israel，Japan 等 2 个
申办方
AbbVie
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT06639074

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

适用疾病
Advanced Fallopian Tube Carcinoma；Advanced Fallopian Tube High Grade Serous Adenocarcinoma；Advanced Ovarian Carcinoma
干预
Biopsy，Biospecimen Collection，Computed Tomography，Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
地点
United States
申办方
Mayo Clinic
正在招募 Phase 1, Phase 2 生物制剂器械
clinicaltrials.gov NCT05329532

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

适用疾病
Triple Negative Breast Cancer；Renal Cell Cancer；High Grade Ovarian Serous Adenocarcinoma
干预
Modi-1 Moditope，Pembrolizumab，MicronJet600™ microneedle device (NanoPass)
地点
United Kingdom
申办方
Scancell Ltd
正在招募 Phase 2 药物
clinicaltrials.gov NCT05512208

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

适用疾病
Endometrioid Cancer；Mucinous Ovarian Cancer；High Grade Serous Ovarian Cancer
干预
Avutometinib (VS-6766) + defactinib
地点
United States
申办方
University of Oklahoma
即将招募 Phase 2 药物手术/操作
clinicaltrials.gov NCT07432594

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

适用疾病
High-grade Serous Ovarian Cancer (HGSOC)；Fallopian Tube Cancers；Primary Peritoneal Cancer
干预
Aitua Combination Antibody，Albumin-Bound Paclitaxel /nab-Paclitaxel，Carboplatin (AUC 5)，Interval Debulking Surgery
地点
未列出
申办方
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
正在招募 Phase 3 生物制剂药物
clinicaltrials.gov NCT05281471

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

适用疾病
Platinum-resistant Ovarian Cancer；Platinum-refractory Ovarian Cancer；Fallopian Tube Cancer
干预
olvimulogene nanivacirepvec，Platinum chemotherapy: carboplatin (preferred) or cisplatin，Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，Bevacizumab (or biosimilar)
地点
United States
申办方
Genelux Corporation
正在招募 Phase 3 药物
clinicaltrials.gov NCT07546500

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

适用疾病
Ovarian Cancer
干预
Investigator's choice of Chemotherapy，Azenosertib
地点
United States，Australia，Belgium，Canada 等 8 个
申办方
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
正在招募 Phase 1 药物手术/操作
clinicaltrials.gov NCT05950464

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

适用疾病
Recurrent Endometrial Carcinoma；Recurrent Endometrial Clear Cell Adenocarcinoma；Recurrent Endometrial Endometrioid Adenocarcinoma
干预
BET Bromodomain Inhibitor ZEN-3694，Biopsy Procedure，Biospecimen Collection，Computed Tomography
地点
United States
申办方
National Cancer Institute (NCI)
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05902988

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

适用疾病
Advanced Solid Tumor；High Grade Serous Adenocarcinoma of Ovary；Squamous Non-small-cell Lung Cancer
干预
VLS-1488
地点
United States
申办方
Volastra Therapeutics, Inc.
即将招募 阶段未标明 生物制剂
clinicaltrials.gov NCT07455071

A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

适用疾病
HRD-negative Epithelial Ovarian Cancer
干预
Tumor Neoantigen-Sensitized Autologous Dendritic Cell Injection (YS247)
地点
未列出
申办方
Peking University Third Hospital
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05985655

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

适用疾病
Head and Neck Squamous Cell Carcinoma (HNSCC)；Pancreatic Adenocarcinoma；Non-small Cell Lung Cancer (NSCLC)
干预
GTAEXS617，SoC
地点
United States，Belgium，United Kingdom
申办方
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
正在招募 Phase 3 药物
clinicaltrials.gov NCT06828354

A Study of SHR-A1811 in Subjects With Ovarian Cancer

适用疾病
Ovarian Cancer
干预
SHR-A1811，Paclitaxel Injection，Doxorubicin Hydrochloride Liposome Injection，Gemcitabine Hydrochloride for Injection
地点
China
申办方
Jiangsu HengRui Medicine Co., Ltd.
正在招募 Phase 1 生物制剂
clinicaltrials.gov NCT06242470

A Study of MGC026 in Participants With Advanced Solid Tumors

适用疾病
Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预
MGC026 Dose Escalation，MGC026 Dose for Expansion
地点
United States，Australia，United Kingdom
申办方
MacroGenics
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT06483048

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

适用疾病
Platinum-Resistant Fallopian Tube Carcinoma；Platinum-Resistant Ovarian Carcinoma；Platinum-Resistant Primary Peritoneal Carcinoma
干预
Autologous MUC1-activated T-cells，Bendamustine，Biospecimen Collection，Computed Tomography
地点
United States
申办方
Mayo Clinic
正在招募 Phase 2 生物制剂
clinicaltrials.gov NCT06730347

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

适用疾病
Platinum-resistant Ovarian Cancer；Platinum-Resistant Fallopian Tube Carcinoma；Platinum-Resistant Primary Peritoneal Carcinoma
干预
Lorigerlimab
地点
United States，Canada，South Korea
申办方
MacroGenics
正在招募 Phase 2 药物
clinicaltrials.gov NCT06682988

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

适用疾病
Advanced High-Grade Epithelial Ovarian Cancer；Primary Peritoneal Cancer；Fallopian Tube Cancers
干预
Mirvetuximab Soravtansine
地点
United States，Australia，Belgium，France 等 4 个
申办方
AbbVie
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

适用疾病
Advanced Solid Tumor；Metastatic Solid Tumor；Soft Tissue Sarcoma (STS)
干预
GI-102 subcutaneous (SC)，GI-102，doxorubicin，paclitaxel
地点
United States，South Korea
申办方
GI Innovation, Inc.
第 1 页

Subtypes

建议拆分方向

high-grade serous ovarian cancerBRCA mutationHRDplatinum-sensitiveplatinum-resistantPARP inhibitorrecurrent ovarian cancer

Keywords

英文搜索关键词

ovarian cancer high-grade serous ovarian cancer recurrent ovarian cancer BRCA ovarian cancer HRD ovarian cancer platinum-resistant ovarian cancer platinum-sensitive ovarian cancer PARP inhibitor ovarian cancer

Keyword guide

这些关键词怎么理解

术语中文意思对找临床试验有什么用
高级别浆液性卵巢癌 / High-grade serous 卵巢癌中常见且研究较多的病理类型。 很多试验会限定 high-grade serous 或 epithelial ovarian cancer。
BRCA mutation BRCA1/2 突变可能与 DNA 修复相关。 可以找 PARP 抑制剂、DNA damage repair 相关试验。
HRD 同源重组修复缺陷，是一类 DNA 修复相关状态。 PARP 或联合治疗试验可能要求 HRD 状态。
Platinum-sensitive 通常指含铂治疗后较长时间才复发，具体定义看试验。 很多复发卵巢癌试验会按铂敏感分组。
Platinum-resistant 通常指含铂治疗后较短时间内进展或复发。 铂耐药卵巢癌有专门试验方向，如 ADC、免疫或靶向联合。

Recruitment status

常见招募状态

Recruiting正在招募，可能仍可申请参加。
Not yet recruiting尚未开始招募，可关注后续开放时间。
Active, not recruiting试验仍在进行，但通常不再招新患者。
Completed试验已经完成。
Terminated试验提前终止。
Unknown公开页面上的状态不明确或未及时更新。

Before contact

联系前准备资料

  • 病理诊断报告
  • 影像报告：CT / MRI / PET-CT
  • 既往治疗记录
  • 用药历史
  • 基因检测报告
  • 最近血液检查结果
  • 出院小结
  • 主治医生英文病情摘要，如果有
  • 护照和签证情况，如果考虑出国

Filters

搜索时重点关注

  • Recruiting / Not yet recruiting
  • Location
  • Age
  • Phase
  • Inclusion Criteria
  • Exclusion Criteria
  • Prior treatments
  • Biomarker / mutation requirements
  • ECOG performance status
  • 是否接受 international patients
  • 是否需要长期停留在试验所在地
  • 费用、保险、翻译、住宿和陪护安排

Ask your doctor

可以带去问医生的问题

  • 我的病理类型是否符合这个试验？
  • 我之前用过的药会不会影响入组？
  • 我是否需要做基因检测？
  • 这个试验是几期？主要目的是什么？
  • 参加试验会不会影响当前治疗？
  • 如果去国外参加，风险和成本大概有哪些？
  • 研究团队是否接受海外患者？
下一步提示

请将检索到的临床试验信息带给主治医生或肿瘤科医生讨论。本站不判断患者是否适合任何临床试验。